
Tennessee Oncology appointed Stephen Schleicher, MD, MBA, as Chief Medical Officer (CMO), with president Natalie Dickson, MD, being promoted from CMO to Chief Strategy Officer (CSO).

Tennessee Oncology appointed Stephen Schleicher, MD, MBA, as Chief Medical Officer (CMO), with president Natalie Dickson, MD, being promoted from CMO to Chief Strategy Officer (CSO).

Jeffrey Patton, MD, is the CEO of OneOncology, a national partnership of independent community oncologists based in Nashville, Tennessee. He is also executive chairman of the board, Tennessee Oncology, and a member of the board, Community Oncology Alliance.

Duncan Allen, MHA, introduced the audience to the OneR clinical research initiative, and Jeffrey Patton, MD, discussed how the hospital transparency law has bolstered the case for the value of community oncology.

The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.

The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.

Physician and health policy advocates praised the emphasis on streamlining models and ending silos, but practices that invested in the Oncology Care Model (OCM) await key details.


Experts who took part in Patient-Centered Oncology Care® 2021 said when guidelines recommend high-cost targeted therapies or immunotherapies, the focus must turn to areas such as imaging, diagnostic tests, and other elements that contribute to the cost of care.

With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.

Having the option of receiving care in their community instead of a large hospital located hours away is not only a benefit for many patients, but research is showing community oncology practices are a low-cost, high-quality provider of care, explained Jeff Patton, MD, executive chairman of Tennessee Oncology and CEO of OneOncology.


Davey Daniel, MD, an oncologist with Tennessee Oncology in Chattanooga, spoke with The American Journal of Managed Care® (AJMC®) about the withdrawal of indications in small cell lung cancer (SCLC) for the PD-1 inhibitors pembrolizumab and nivolumab.


Originally set to expire on June 30, 2021, the Oncology Care Model was extended for an additional year in light of the COVID-19 pandemic.

Biomarker testing and remote patient monitoring are just 2 areas of research presented during the annual meeting of the American Society of Clinical Oncology (ASCO).

Davey Daniel, MD, hematology/medical oncology specialist, Tennessee Oncology, discusses findings of an abstract presented at ASCO 2021 showing a lower total cost of care paid by Medicare for episodes of care for patients in the Oncology Care Model (OCM) enrolled in clinical trials vs those receiving routine care.

Edward Licitra, MD, PhD, medical oncologist, Astera Health Partners, discusses his thoughts on what value-based cancer care entails and how physicians can best align their goals with those of the patient and health plan.

Day 1 of this year’s virtual Community Oncology Conference opened with a panel discussion that touched on all things related to the COVID-19 pandemic, with leaders presenting a unified front.

Jeff Patton, MD, CEO, OneOncology, and chairman of the board, Tennessee Oncology, discusses what influence COVID-19 will have on discussions at the Community Oncology Conference 2021, as well as takeaways he hopes audience members and participants gain from the conference.

Dinesh Kapur, MD, chair, OneCouncil, and managing partner, Eastern Connecticut Hematology and Oncology (ECHO), speaks on efforts made by by community oncology practices to improve minority representation in oncology clinical trials and implications of the COVID-19 pandemic ahead of the 2021 Community Oncology Conference.

Jeff Patton, MD, CEO, OneOncology, chairman of the board, Tennessee Oncology, discusses what audience members should expect from the Community Oncology Conference 2021 and sessions he is looking forward to.

Arizona Blood and Cancer Specialists, OneOncology, and TMC HealthCare announce 2 free-standing imaging centers.

Managing the constantly evolving selection of therapies in oncology can be difficult, but is of the utmost importance to get the right treatment to the right patient, agreed a panel at Patient-Centered Oncology Care® 2020.

A first-of-its-kind partnership between OneOncology and Genentech aims to bring more personalized cancer care to community oncology centers nationwide.

The launch comes as major cancer research organizations are calling for ways to increase diversity in clinical trials.

Janice Baker joins high-growth OneOncology platform as chief human resources officer and Jon Billington steps into chief financial officer role.

More than 200,000 American men are diagnosed with prostate cancer each year.

A community oncology practice network and a cancer genomics firm announced an initiative to expand opportunities for real-time precision medicine as well as research participation.

Los Angeles Cancer Network is joining the OneOncology platform.

OneOncology, the national partnership of independent oncology practices, today appointed John Fox, MD as Medical Director, Managed Care.